Brief: Prostatype Genomics Reports H2 EBITDA Of SEK -17.8 Mln
26/02/2026 15:59
Feb 26 (Reuters) - Prostatype Genomics AB PROGEN.ST: H2 2025 NET SALES AMOUNTED TO SEK 348,000 H2 2025 EBITDA SEK -17.8 MILLION H2 2025 CASH FLOW FROM OPERATING ACTIVITIES SEK -6.72 MILLION WE WILL GROW IN SALES, STRENGTHEN OUR INNOVATION POWER AND CONTINUE TO FOCUS ON BUILDING VALUE FOR OUR SHAREHOLDERS Source text: ID:nMFND8MnK Further company coverage: PROGEN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Prostatype Genomics AB
See all newsBrief: Prostatype Genomics Cannot Specify Timing For Final Medicare Decision
Brief: Prostatype Genomics Enters SEK 6.0 Mln Agreement With Vator Securities For To6
Brief: Prostatype Genomics AB H1 2026 Net Sales SEK 457,000
Brief: Prostatype Genomics Resolves On Directed Issue
Brief: Prostatype Genomics To Receive About SEK 47.4 Mln From Rights Issue